Brief: Ocumension Therapeutics' Unit And Alimera Entered Into Exclusive License Agreement
14/04/2021 16:13
April 14 (Reuters) - Ocumension Therapeutics 1477.HK :
* UNIT AND ALIMERA ENTERED INTO EXCLUSIVE LICENSE AGREEMENT
* CONSIDERATION INCLUDES UPFRONT PAYMENT IN AMOUNT OF US$10
MLN
* CONSIDERATION ALSO INCLUDES AGGREGATED POTENTIAL SALES
MILESTONE
PAYMENT IN AMOUNT OF UP TO US$89 MLN
* ALIMERA TO GRANT GROUP LICENSING RIGHTS OF ALIMERA'S 190
MICROGRAM FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN
APPLICATOR
Source text for Eikon: ID:nHKS2p5NCP
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application